MagForce AG

  • ISIN: DE000A0HGQF5
  • Land: Deutschland

Nachricht vom 19.09.2019 | 08:30

MagForce AG to host Lunch Symposium on Local Therapies in Malignant Gliomas during the 19th European Congress of Neurosurgery (EANS2019)

DGAP-Media / 19.09.2019 / 08:30

MagForce AG to host Lunch Symposium on Local Therapies in Malignant Gliomas during the 19th European Congress of Neurosurgery (EANS2019)

Berlin, Germany and Nevada, USA, September 19, 2019 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled "Local Therapies in Malignant Gliomas - update and new perspectives" during the 19th European Congress of Neurosurgery in Dublin, Ireland.

Chaired by Prof. Dr. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital of Münster (UKM), Germany, the one-hour lunch symposium will feature two keynote speeches: After an introduction and overview on the current status of glioma treatments by Prof. Dr. Stummer, Ricardo Díez Valle, MD PHD, Head of the Department of Neurosurgery, Hospital Group Quirón Madrid, Spain, will give an update on local neurosurgical therapies. The symposium will be rounded off with a talk from Prof. Dr. Stummer on "An Emerging Adjunct: NanoTherm(R) - NanoPaste Application". During the subsequent wrap-up and discussion, participants will have the opportunity to ask questions.

Symposium details:

Title: Local Therapies in Malignant Gliomas
Update and new perspectives
NanoTherm(R) - NanoPaste Application
Date: Wednesday, September 25, 2019
Time: 1.15-2.15 p.m. local time/GMT
Location:                   EcoCem meeting room, The Convention Centre Dublin
Speakers: Prof. Dr. Walter Stummer (Chair)
University Hospital of Münster, Germany
Current Status of Glioma Treatments

Ricardo Díez Valle, MD PHD
Hospital Group Quirón Madrid, Spain
Local Neurosurgical Therapies: An Update

Prof. Dr. Walter Stummer
University Hospital of Münster, Germany
An Emerging Adjunct: NanoTherm(R) - NanoPaste Application

In addition to the lunch symposium, MagForce will host "Meet the Expert" sessions on Thursday, September 26th and Friday, September 27th, at 10 a.m. respectively, at the MagForce booth No. 35 located at Level 0 - The Forum. On both days, Dr. Michael Schwake, Senior Physician in the Department of Neurosurgery at the University Hospital of Münster and member of Prof. Dr. Stummer's team, will be available to interested participants for questions as an expert in the use of the NanoTherm therapy system in clinical practice.

Prof. Dr. Stummer and his team at the University Hospital of Münster have been treating brain tumor patients with MagForce's NanoTherm therapy since early 2015 and were the first to introduce, clinically, the new nanoparticles application technique called 'NanoPaste'. In previous clinical research, the UKM team demonstrated that a better applicability of heat-focussing nanoparticles around the resection rim after surgical removal of a brain tumor could boost the thermotherapy treatment for tumor ablation and as a radiosensitiser in glioma therapy. With the use of the new NanoPaste technique, the team was able to create sufficient nanoparticle concentrations to reach effective thermotherapy in the glioma resection cavity wall and its vicinity, allowing for more control of remaining tumor infiltration. Especially in comparison to stereotactic techniques with their associated imponderabilities in scarred and pretreated tissues, the 'NanoPaste' application was technically easy, controllable and quick to perform.

About NanoTherm Therapy
MagForce's NanoTherm therapy provides a novel, nanotechnology-based approach for the treatment of solid tumors by introducing magnetic nanoparticles either directly into the tumor or into the resection cavity wall. These particles are subsequently heated by an alternating magnetic field that allows targeted treatment by irreparably destroying, or weakening, cancer cells making them more sensitive to concomitant radiotherapy or chemotherapy. Since the particles remain at the site of application due to their special coating, the surrounding healthy tissue is spared and repeated treatments as well as the integration into multimodal therapy concepts are made possible. MagForce AG was granted the European CE certificate ("European Certification") in 2011 and thus the official approval of NanoTherm therapy for the treatment of brain tumors in Germany and all member states of the European Union.

About EANS2019
The European Association of Neurosurgical Societies (EANS) is both an independent federation of European national neurosurgical societies and a fast-developing association of individual neurosurgeons from around the world, aiming to enhance the quality of neurosurgical patient care through training, education and research. A key way in which the association fulfils this objective is by facilitating the exchange of scientific information at the highest level through the organisation of meetings, symposia and educational courses - with the annual congress as its flagship event.

The overall scientific programme will take the familiar form that has been established over the last few years bringing together international experts to discuss and inform. To help develop best practice in all subspecialities under the headings of Technology, Techniques, Training and increasingly important Transparency. The four days of scientific discussions offer plenty of opportunities for meetings, socialising and hearing of the latest scientific developments.

For more information on the EANS2018 programme, please click here:

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit:
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.


Barbara von Frankenberg
Vice President
Communications & Investor Relations

T +49-30-308380-77

End of Media Release

Issuer: MagForce AG
Key word(s): Health

19.09.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.


Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen

14. Juli 2020, 16:38

Aktuelle Research-Studie

Original-Research: German Real Estate Capital S.A. (von GBC AG): Management Interview German Real Estate Capital S.A.

14. Juli 2020